Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $60

Author: Benzinga Newsdesk | March 20, 2024 06:35am

HC Wainwright & Co. analyst Douglas Tsao maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the price target from $50 to $60.

Posted In: CRNX